The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Bioeng. Biotechnol.
Sec. Nanobiotechnology
Volume 12 - 2024 |
doi: 10.3389/fbioe.2024.1514245
This article is part of the Research Topic Advances in Nanomedicine: Revolutionizing Healthcare with Nanoscale Innovations View all 3 articles
Intrinsic Anti-inflammatory Nanomedicines for Enhanced Pain Management
Provisionally accepted
Bin Qiao
1
Jiaqian Yao
1
Yu'ang Fan
2
Na Zhang
2*
Miao Feng
2*
Jiaju Zhao
1*
Xinye Song
2*
Yong Luan
2*
Bowen Zhuang
1*
Nan Zhang
1*
Xiaoyan Xie
1*
Ming Xu
1*- 1 The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 2 Department of Anesthesia, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning Province, China
Effective postoperative pain management remains a significant challenge due to the severe side effects of opioids and the limitations of existing analgesic delivery systems. Inflammation plays a critical role in pain exacerbation, highlighting the need for therapies that combine analgesic effects with intrinsic anti-inflammatory properties. Herein, we develop an intrinsic anti-inflammatory nanomedicine designed to enhance pain management by integrating controlled anesthetic release with inherent anti-inflammatory activity. Our nanoplatform utilizes dendritic mesoporous silica nanoparticles (MSNs) loaded with levobupivacaine and coated with Rg3-based liposomes derived from ginsenoside Rg3, termed LMSN-bupi. The MSNs enable sustained and controlled release of the local anesthetic, while the Rg3-liposome coating provides intrinsic anti-inflammatory effects by inhibiting macrophage activation and reducing nanoparticle uptake. In animal models, LMSN-bupi demonstrates significantly prolonged analgesic effects and attenuated inflammatory responses compared to traditional liposome-decorated nanoparticles (TMSN-bupi)(n=5). These findings underscore the potential of intrinsic anti-inflammatory nanomedicines in enhancing pain management, offering a promising strategy to overcome the limitations of current therapies and improve patient outcomes in postoperative care.
Keywords: ：pain, Inflammation, Levobupivacaine, Nanomedicine, Ginsenoside Rg3
Received: 20 Oct 2024; Accepted: 29 Nov 2024.
Copyright: © 2024 Qiao, Yao, Fan, Zhang, Feng, Zhao, Song, Luan, Zhuang, Zhang, Xie and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Na Zhang, Department of Anesthesia, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning Province, China
Miao Feng, Department of Anesthesia, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning Province, China
Jiaju Zhao, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Xinye Song, Department of Anesthesia, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning Province, China
Yong Luan, Department of Anesthesia, First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning Province, China
Bowen Zhuang, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Nan Zhang, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Xiaoyan Xie, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Ming Xu, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.